WO2009047800A3 - Oral controlled release composition of carvedilol - Google Patents

Oral controlled release composition of carvedilol Download PDF

Info

Publication number
WO2009047800A3
WO2009047800A3 PCT/IN2008/000652 IN2008000652W WO2009047800A3 WO 2009047800 A3 WO2009047800 A3 WO 2009047800A3 IN 2008000652 W IN2008000652 W IN 2008000652W WO 2009047800 A3 WO2009047800 A3 WO 2009047800A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
controlled release
oral controlled
pharmaceutically acceptable
release composition
Prior art date
Application number
PCT/IN2008/000652
Other languages
French (fr)
Other versions
WO2009047800A2 (en
Inventor
Ashish Guha
Bharat Metkar
Makrand Krishnakumar Avachat
Original Assignee
Lupin Ltd
Ashish Guha
Bharat Metkar
Makrand Krishnakumar Avachat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd, Ashish Guha, Bharat Metkar, Makrand Krishnakumar Avachat filed Critical Lupin Ltd
Publication of WO2009047800A2 publication Critical patent/WO2009047800A2/en
Publication of WO2009047800A3 publication Critical patent/WO2009047800A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

An oral controlled release pharmaceutical composition comprising a carvedilol or a pharmaceutically acceptable salt(s) thereof. The oral controlled release pharmaceutical composition comprises a core comprising a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt(s) thereof and/or other pharmaceutically acceptable excipient thereof; and a functional coating comprising one or more pH dependent polymer(s), water soluble pore forming agent and/or other pharmaceutically acceptable excipient(s) thereof.
PCT/IN2008/000652 2007-10-09 2008-10-08 Oral controlled release composition of carvedilol WO2009047800A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1385/KOL/2007 2007-10-09
IN1385KO2007 2007-10-09

Publications (2)

Publication Number Publication Date
WO2009047800A2 WO2009047800A2 (en) 2009-04-16
WO2009047800A3 true WO2009047800A3 (en) 2009-08-13

Family

ID=40275982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000652 WO2009047800A2 (en) 2007-10-09 2008-10-08 Oral controlled release composition of carvedilol

Country Status (1)

Country Link
WO (1) WO2009047800A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
WO2004056336A2 (en) * 2002-12-20 2004-07-08 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
WO2007023325A2 (en) * 2005-08-26 2007-03-01 Egis Gyógyszergyár Nylvánosan Müködo Részvénytársaság Controlled release pharmaceutical composition containing carvedilol
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
WO2008083130A2 (en) * 2006-12-26 2008-07-10 Dr. Reddy's Laboratories Limited Amorphous and crystalline form a of carvedilol phosphate

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
WO2004056336A2 (en) * 2002-12-20 2004-07-08 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
WO2007023325A2 (en) * 2005-08-26 2007-03-01 Egis Gyógyszergyár Nylvánosan Müködo Részvénytársaság Controlled release pharmaceutical composition containing carvedilol
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
WO2008083130A2 (en) * 2006-12-26 2008-07-10 Dr. Reddy's Laboratories Limited Amorphous and crystalline form a of carvedilol phosphate

Also Published As

Publication number Publication date
WO2009047800A2 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2007133583A3 (en) Zero-order modified release solid dosage forms
WO2008081891A1 (en) Orally disintegrating solid preparation
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
WO2011084618A3 (en) Compositions and methods for oral drug delivery
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2006084164A8 (en) Gastric retention and controlled release delivery system
PL1906939T3 (en) Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values
WO2009047802A3 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
MX352326B (en) Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules.
WO2007109057A3 (en) Solid dosage form containing a taste masked active agent
WO2005123134A3 (en) A controlled release delivery system for metformin
WO2009057138A3 (en) Controlled release pharmaceutical compositions of tolterodine
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
WO2006044077A3 (en) Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
WO2008129517A3 (en) A stabilized delayed release pharmaceutical composition of rabeprazole
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2009149058A3 (en) Modified release niacin formulations
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
WO2007110753A3 (en) Extended release dosage forms of metoprolol
WO2009023761A3 (en) Pharmaceutical compositions comprising ropinirole
WO2007016128A3 (en) Magnesium salt proton pump inhibitor dosage forms
WO2009027786A3 (en) Matrix dosage forms of varenicline
WO2010018175A3 (en) Oral pharmaceutical formulation for omeprazole comprising a specific separation layer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837487

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08837487

Country of ref document: EP

Kind code of ref document: A2